James M. Mock
Net Worth

Last updated:

What is James M. Mock net worth?

The estimated net worth of Mr. James M. Mock is at least $15,691,438 as of 24 Jun 2022. He has earned $2,091,438 from insider trading and has received compensation worth at least $13,600,000 in PerkinElmer, Inc..

What is the salary of James M. Mock?

Mr. James M. Mock salary is $2,720,000 per year as Senior Vice President & Chief Financial Officer in PerkinElmer, Inc..

How old is James M. Mock?

Mr. James M. Mock is 48 years old, born in 1977.

What stocks does James M. Mock currently own?

As insider, Mr. James M. Mock owns shares in one company:

Company Title Shares Price per share Total value
PerkinElmer, Inc. (PKI) Senior Vice President & Chief Financial Officer 27,577 $0 $0

What does PerkinElmer, Inc. do?

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

James M. Mock insider trading

PerkinElmer, Inc.

Mr. James M. Mock has made 5 insider trades between 2020-2022, according to the Form 4 filled with the SEC. Most recently he sold 663 units of PKI stock worth $97,023 on 24 Jun 2022.

The largest trade he's ever made was exercising 6,080 units of PKI stock on 20 Sep 2021. As of 24 Jun 2022 he still owns at least 27,577 units of PKI stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 663 $146.34 $97,023
Sale
Common Stock 2,290 $145.78 $333,836
Sale
Common Stock 2,072 $144.9 $300,233
Sale
Common Stock 6,080 $185.61 $1,128,509
Sale
Common Stock 5,623 $41.23 $231,836

PerkinElmer key executives

PerkinElmer, Inc. executives and other stock owners filed with the SEC: